John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Cancer in elderly: What practical tools to guide treatment? Volume 24, supplement 3, Novembre 2017

Figures

  • Figure 1

Tables

Authors
1 Hôpital Avicenne, service de médecine gériatrique, unité de coordination en oncogériatrie, 93000, Bobigny, France
2 Université Paris 13, Sorbonne Paris Cité, Laboratoire Educations et Pratiques de Santé (LEPS) EA3412, 93017, Bobigny, France
3 CHU Poitiers, service de gériatrie, France
4 Université Paris-Est, UPEC, DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), 94000, Créteil, France
5 Hôpital Henri-Mondor, département de médecine interne et gériatrie, unité de coordination en oncogériatrie, 94000, Créteil, France
* Tirés à part

With aging of population, the incidence of cancer patients aged 65 and over increases. While older cancer patients were most often excluded from clinical trials, the extrapolation of therapeutics in this population remains difficult to implement. Thus, the scientific societies recommend that a comprehensive geriatric assessment (CGA) to be performed in patients aged more than 70 and selected using screening tools for frailty such as the G8 index. The CGA allows detecting aging-related vulnerabilities in various domains (social, comorbidities, autonomy, nutrition, mobility, mood, cognition) and associated with adverse outcomes during cancer treatment (reduced overall survival, perioperative complications, toxicity-related chemotherapy). Nevertheless, to date, no algorithms based on CGA are validated to guide the therapeutic decision in geriatric oncology. The collaboration between geriatricians and oncologists is essential. This article presents the set of tools and scores used in geriatric oncology to guide the therapeutic decision.